Repros Therapeutics Inc. (RPRX) Reports Issuance of Two Additional U.S. Androxal® Patents
4/10/2013 11:11:37 AM
THE WOODLANDS, Texas, April 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) announced two patents representing potentially large commercial indications for its drug Androxal have been issued. The two patents deal with the metabolic consequences of low testosterone and the positive outcomes associated with restoration of testicular function exhibited by Androxal. The 8,377,991 patent specifically covers treatment of Type 2 diabetes, an area of high unmet medical need. The 991 issuance and patent life should have a positive impact on Androxal's long-term commercial potential.